These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 37500184

  • 1. Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk.
    Tardelli V, Xu KY, Bisaga A, Levin FR, Fidalgo TM, Grucza RA.
    BMJ Ment Health; 2023 Jul; 26(1):. PubMed ID: 37500184
    [Abstract] [Full Text] [Related]

  • 2. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA.
    JAMA Netw Open; 2022 May 02; 5(5):e2211363. PubMed ID: 35536575
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY, Presnall N, Mintz CM, Borodovsky JT, Bhat NR, Bierut LJ, Grucza RA.
    JAMA Netw Open; 2021 Feb 01; 4(2):e210061. PubMed ID: 33625511
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA, Bohnert ASB, Blow FC, Gordon AJ, Ignacio RV, Kim HM, Ilgen MA.
    Addiction; 2021 Jan 01; 116(1):96-104. PubMed ID: 32428386
    [Abstract] [Full Text] [Related]

  • 8. Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder.
    Mintz CM, Xu KY, Presnall NJ, Hartz SM, Levin FR, Scherrer JF, Bierut LJ, Grucza RA.
    JAMA Netw Open; 2022 May 02; 5(5):e2211634. PubMed ID: 35544135
    [Abstract] [Full Text] [Related]

  • 9. Adverse events among adult Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
    O'Brien P, Henke RM, Schaefer MB, Lin J, Creedon TB.
    Drug Alcohol Depend; 2021 Apr 01; 221():108555. PubMed ID: 33596496
    [Abstract] [Full Text] [Related]

  • 10. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW, Larochelle MR, Saitz R, Wang N, Bernson D, Walley AY.
    Addiction; 2020 May 01; 115(5):924-932. PubMed ID: 31916306
    [Abstract] [Full Text] [Related]

  • 11. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR, Mack A, Chandler RK, Fanucchi LC, Feaster DJ, LaRochelle MR, Lofwall MR, Nau M, Villani J, Walsh SL, Westgate PM, Slavova S, Talbert JC.
    JAMA Netw Open; 2023 Oct 02; 6(10):e2336914. PubMed ID: 37851446
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY, Schiff DM, Jones HE, Martin CE, Kelly JC, Bierut LJ, Carter EB, Grucza RA.
    J Gen Intern Med; 2023 Dec 02; 38(16):3499-3508. PubMed ID: 37436568
    [Abstract] [Full Text] [Related]

  • 15. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T, McCormack D, Bozinoff N, Tadrous M, Antoniou T, Munro C, Campbell T, Paterson JM, Mamdani M, Sproule B.
    Addiction; 2022 Jul 02; 117(7):1972-1981. PubMed ID: 35257434
    [Abstract] [Full Text] [Related]

  • 16. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM, Shoff C, Blanco C, Losby JL, Ling SM, Compton WM.
    JAMA Psychiatry; 2023 May 01; 80(5):508-514. PubMed ID: 36988913
    [Abstract] [Full Text] [Related]

  • 17. Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis.
    Xu KY, Borodovsky JT, Presnall N, Mintz CM, Hartz SM, Bierut LJ, Grucza RA.
    Am J Psychiatry; 2021 Jul 01; 178(7):651-659. PubMed ID: 33653119
    [Abstract] [Full Text] [Related]

  • 18. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R.
    J Clin Psychol; 2023 Dec 01; 79(12):2869-2883. PubMed ID: 37584532
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
    Jakubowski A, Lu T, DiRenno F, Jadow B, Giovanniello A, Nahvi S, Cunningham C, Fox A.
    J Subst Abuse Treat; 2020 Dec 01; 119():108140. PubMed ID: 33138925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.